Polyphor AG - ESG Rating & Company Profile powered by AI
Full Sustainability assessment of Polyphor AG are accessed by signing up for free. This webpage displays a zero-cost E,S&G assessment for Polyphor AG. Browse to the end of this webpage for potential risks for Polyphor AG based on sector, location and marketcap.
Polyphor AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 5.3 and governance score of 2.7.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
| 989 | Tricida Inc | 4.1 | High |
| 1004 | Polyphor AG | 4.0 | High |
| 1004 | Can B Corp | 4.0 | High |
| 1004 | CLS Holdings USA Inc | 4.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Polyphor AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Polyphor AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Polyphor AG report the average age of the workforce?
Sign up for free to unlockDoes Polyphor AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Polyphor AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Polyphor AG disclose cybersecurity risks?
Sign up for free to unlockDoes Polyphor AG offer flexible work?
Sign up for free to unlockDoes Polyphor AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Polyphor AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Polyphor AG conduct supply chain audits?
Sign up for free to unlockDoes Polyphor AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Polyphor AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Polyphor AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Polyphor AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Polyphor AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Polyphor AG disclose water use targets?
Sign up for free to unlockDoes Polyphor AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Polyphor AG have a product recall in the last two years?
Sign up for free to unlockDoes Polyphor AG disclose incidents of discrimination?
Sign up for free to unlockDoes Polyphor AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Polyphor AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Polyphor AG disclose parental leave metrics?
Sign up for free to unlockDoes Polyphor AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Polyphor AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Polyphor AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Polyphor AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Polyphor AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Polyphor AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Polyphor AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Polyphor AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Polyphor AG disclose its waste policy?
Sign up for free to unlockDoes Polyphor AG report according to TCFD requirements?
Sign up for free to unlockDoes Polyphor AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Polyphor AG disclose energy use targets?
Sign up for free to unlockDoes Polyphor AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Polyphor AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Polyphor AG
These potential risks are based on the size, segment and geographies of the company.
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.